Anti-Human HLA-DR (L243) ColorWheel^® Dye-Ready mAb

ColorWheel^® technology is a novel and proprietary method of creating your own antibody and dye combinations for use in flow cytometry. By incubating any ColorWheel^® antibody with any ColorWheel^® dye, researchers can quickly and simply produce primary conjugated antibodies for use in single color or multicolor flow cytometry analysis. Each ColorWheel^® antibody and dye is lyophilized for long-term storage, allowing for simplicity and flexibility without compromise. ColorWheel^® technology requires both ColorWheel^® antibody and ColorWheel^® dye for Flow Cytometry application.

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This product is Preservative-free, lyophilized product for enhanced stability and allow for ambient shipping and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

Clone L243 is a mouse monoclonal antibody that detects HLA-DR.

Human B lymphocytes.

Quality Control Testing

Evaluated by Flow Cytometry in Human PBMCs.

Flow Cytometry Analysis: Staining of one million Human peripheral blood mononuclear cells (PBMC) was performed using 5 μL of a 1:1 mixture of Cat. No. CWA-1041, Anti-Human HLA-DR (L243) ColorWheel^® Dye-Ready mAb and Cat. No. CWDS-PE ColorWheel^® Antibody-Ready Phycoerythrin (PE) Dye or an equivalent amount of PE-conjugated Mouse IgG2a isotype control.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

MHC class II antigen (UniProt: O19762; also known as Human leukocyte antigen DR, HLA-DR) is encoded by the HLA-DR gene (Gene ID: 3122) in human. HLA-DR is a heterodimeric, single-pass type I membrane protein present on endosomal and lysosomal membranes. It contains a single transmembrane domain localized in amino acids 186-208. Its expression is observed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other nonprofessional antigen-presenting cells. It is recognized as a marker of T cell activation and its levels are elevated in cytotoxic T cells (CTLs) in autoimmune diseases and in subjects with HIV infection. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is reported to be critical for efficient peptide presentation to CD4+ T cells. The complex formed by HLA-DR molecules and peptides is specifically recognized by the antigen receptor of CD4+ helper T lymphocytes. HLA-DR expressing CTLs produce interferon- and Granzyme B, indicating their effector and probable anti-tumor activity profile. Significantly reduced expression of HLA-DR and increased level of PD-1 is observed under conditions of sepsis. (Ref.: Saraiva, DP., et al. (2018). Front. Immunol. 9; 2605; Zhuang, Y., et al. (2017). Front. Biosci. (Landmark Ed). 22;1344-1354).

Lyophilized from PBS containing D-Mannitol and Sucrose, normal appearance is a dried pellet. Reconstituted antibody solution is stable and functional as assessed by functional testing. Contains no biocide or preservatives, such as azide.

1.0 mg/mL after reconstitution at 25 μL in PBS. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C. Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial. Reconstitute each vial by adding 25 μL PBS. Protect from light.

ColorWheel is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.